


PHARMACEUTICAL 2019

uniQure N.V. Rank 138 of 371







PHARMACEUTICAL 2019

uniQure N.V. Rank 138 of 371



The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of uniQure N.V. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is -82%, being 249% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	236,576
Cost of Goods Sold	0
Intangible Assets	5,707
Liabilities, Current	19,969
Liabilities, Non-Current	74,331
Other Assets	2,444
Other Compr. Net Income	-5,261
Other Expenses	3,939
Other Liabilities	0
Other Net Income	9,465
Property and Equipment	29,179
Research and Development	74,809
Revenues	11,284
Selling, General and Administrative Expense	25,305

Output Variable	Value in 1000 USD
Assets	273,906
Liabilities	94,300
Expenses	104,053
Stockholders Equity	179,606
Net Income	-83,304
Comprehensive Net Income	-85,934
Economic Capital Ratio	-82%

